Mobile

An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-scalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in S...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-006170-28

An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-scalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial seizures

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective is to evaluate the safety and tolerability of perampanel (up to12mg/day) given as adjunctive treatment in subjects with refractory partial seizures

Critère d'inclusion

  • Epilepsy: refractory partial seizures with or without secondary generalisation

Liens